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A B S T R A C T   
T Regulatory cells (Tregs) can have both protective and pathological roles. They maintain immune homeostasis 
and inhibit immune responses in various diseases, including cancer. Proportions of Tregs in the peripheral blood 
of some cancer patients increase by approximately two-fold, compared to those in healthy individuals. Tregs 
contribute to cancer development and progression by suppressing T effector cell functions, thereby compro-
mising tumor killing and promoting tumor growth. Highly immunosuppressive Tregs express upregulated levels 
of the transcription factor, Forkhead box protein P3 (FoxP3). Elevated levels of FoxP3 Tregs within the tumor 
microenvironment (TME) showed a positive correlation with poor prognosis in various cancer patients. Despite 
the success of immunotherapy, including the use of immune checkpoint inhibitors, a significant proportion of 
patients show low response rates as a result of primary or acquired resistance against therapy. Some of the 
mechanisms which underlie the development of therapy resistance are associated with Treg suppressive function. 
In this review, we describe Treg contribution to cancer development/progression, and the mechanisms of Treg- 
mediated immunosuppression. We discuss the prognostic significance of FoxP3 Tregs in different cancers and 
their potential use as prognostic biomarkers. We also describe potential therapeutic strategies to target Tregs in 
combination with other types of immunotherapies aiming to overcome tumor resistance and improve clinical 
outcomes in cancer patients. Overall, understanding the prognostic significance of FoxP3 Tregs in various 
cancers and their contribution to therapy resistance could help in the development of more effective targeted 
therapeutic strategies to enhance the clinical outcomes in cancer patients.   
1. Introduction 
T regulatory cells (Tregs) are immunosuppressive subsets of CD4 T 
cells, characterized by the expression of the master regulatory tran-
scription factor, Forkhead box protein P3 (FoxP3), which plays an 
indispensable role in regulating Treg differentiation and development 
[1–3]. Tregs orchestrate cellular and molecular networks to induce an 
immunosuppressive environment favoring tumorigenesis [3–5]. Tregs 
within the tumor microenvironment (TME) are highly activated and 
immunosuppressive, characterized by upregulated levels of FoxP3 [5], 
and Helios [6,7]. Tregs exert suppressive activities on effector cells, such 
as T effector cells (Teffs), natural killer (NK) cells, mono-
cytes/macrophages and antigen-presenting cells (APCs), via various 
mechanisms leading to the induction of apoptosis and inhibition of 
effector cell activation/proliferation [8]. These mechanisms include 
increased consumption of IL-2 and Teff deprivation [9,10], release of 
high levels of interleukin (IL)-10, IL-35, transforming growth factor-beta 
(TGF-β) [11,12], granzyme B and perforin [13], and upregulated levels 
of inhibitory immune checkpoints (ICs), such as cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-1 
(PD-1), lymphocyte activation gene-3 (LAG-3), T-cell immunoreceptor 
with Ig and ITIM domains (TIGIT) and T cell immunoglobulin and mucin 
domain-containing protein 3 (TIM-3) [14]. 
In healthy individuals, Tregs constitute 5–10% of circulating CD4 T 
cells, while they represent significant levels of circulating CD4 T cells 
in the peripheral blood of cancer patients, including those with lung, 
ovarian and gastric cancers, and melanoma [3,15]. In cancer patients, 
the frequency of circulating Tregs increases by approximately 2-fold, 
compared to healthy individuals [16,17]. Additionally, increased 
tumor-infiltrating Tregs has been positively correlated with poor 
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prognosis and low survival rates in various cancer patients, including 
those with lung, ovarian, gastric, breast and pancreatic cancers, head 
and neck squamous cell carcinoma (HNSCC), and melanoma [14,18,19]. 
In solid tumors, the prognostic value of tumor-infiltrating lympho-
cytes (TILs) is one of the most important aspects, which reflects the 
ability of the existing immune response in eradicating tumor cells, and 
predicts the clinical response to a particular cancer therapy. The asso-
ciation between patient survival and the presence of TILs has been 
demonstrated in many tumor types [20–22]. Increased intratumoral 
CD8 T cell infiltration has been associated with increased anti-tumor 
responses and better clinical outcomes following therapy [23,24]. 
However, higher ratios of FoxP3 Tregs:CD8 T cell within the TME is 
one of the major contributing factors to tumor progression and immu-
nosuppression [25–27]. Additionally, FoxP3 Tregs play a central role, 
not only in tumor progression, but also in the development of tumor 
resistance to immunotherapies, such as immune checkpoint inhibitors 
(ICIs), resulting in tumor progression and poor clinical outcomes [8, 
28–32]. Therefore, targeting Tregs alone or in combination with ICIs 
could be beneficial in treating cancer, overcoming Treg-mediated tumor 
resistance, and maximizing the therapeutic efficacy and immune 
responses in cancer patients. 
In this review, we briefly describe Treg contribution to cancer 
development and progression, and outline the mechanisms of Treg- 
mediated immunosuppression. We focus on the prognostic significance 
of FoxP3 Tregs in cancer and their potential use as prognostic bio-
markers. We also describe potential therapeutic approaches to target 
FoxP3 Tregs expressing other Treg-related markers such as CD25, C–C 
chemokine receptor 4 (CCR4), suppressive cytokines and other markers 
alone or in combination with other types of immunotherapies aiming to 
overcome tumor resistance and improve the clinical response in cancer 
patients. 
2. Treg development and trafficking to tumor sites 
CD4FoxP3 Tregs are crucial for the maintenance of immunological 
tolerance; they can develop and differentiate in the thymus (thymus- 
derived Tregs; tTregs) upon the recognition of self-antigens presented by 
thymic stromal cells, including epithelial cells and dendritic cells (DCs) 
[15,33] (Fig. 1). FoxP3 tTregs also express CD25, CTLA-4 along with 
other immune checkpoints, and produce IL-10 and TGF-β [34]. 
Fig. 1. Treg development, recruitment and trafficking to tumor sites. Thymic-derived Tregs (tTregs) expressing FoxP3 are autoreactive T cells, activated upon 
their recognition of self-antigens presented by thymic stromal cells in the medulla and cortex compartments of the thymus. Peripheral Tregs (pTregs) are induced 
from naïve CD4 T cells upon antigen recognition in the secondary lymphoid tissues, such as lymph node or peripheral tissues. In addition to FoxP3 pTregs, there 
are FoxP3  pTregs, which are composed of two subsets with important roles in immune tolerance: Tr1 and Th3 cells (not shown here). tTregs can be also activated, 
while pTregs can be induced in response to antigen recognition by tolerogenic DCs in lymph nodes. FoxP3CD25CTLA-4 tTregs and pTregs expressing chemokine 
receptors including, CCR4, CCR5, CCR10 and CXCR3 are recruited to the TME in a chemotactic gradient induced by chemokines released from tumor cells, TAMs and 
MDSCs, such as CCL17, CCL22, CCL5, CCL28 and CXCL9-11. Within the TME, tumor-derived factors and the suppressive cytokine milieu, comprising TGF-β and IL- 
10, favor Treg survival, differentiation and expansion either via the conversion of FoxP3- T cells into FoxP3 Tregs, by enhancing the recruitment of tTregs and 
pTregs to the TME or supporting the proliferation of existing FoxP3 Tregs within the TME. 
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Additionally, FoxP3 Tregs can differentiate from naïve CD4 T cells 
upon antigen recognition or under certain cytokine conditions in pe-
ripheral tissues [called peripheral Tregs (pTregs)] (Fig. 1), or can be 
generated in vitro [called induced Tregs (iTregs)] [35,36]. pTregs 
consist of other FoxP3  subsets: type 1 T regulatory (Tr1) cells and T 
helper 3 (Th3) cells, which have also been implicated in immune 
tolerance [18,34]. Unlike activated Tregs (CD4CD 
45RA  CD25FoxP3), naïve Tregs (CD4CD45RACD25  FoxP3), 
exhibit a limited immunosuppressive capacity [15,37,38]. As depicted 
in Fig. 1, tTregs and pTregs expressing chemokine receptors are 
recruited to tumor sites via chemotaxis induced by a chemokine gradient 
[39,40]. Tumor cells and tumor-associated immune cells, such as 
tumor-associated macrophages (TAMs) and myeloid-derived suppressor 
cells (MDSCs), release chemokines, such as CCL17, CCL22, CCL5, CCL6 
or CCL28 depending on the tumor type/site, to attract activated Tregs 
expressing chemokine receptors, such as CCR4, CCR5, CCR10 and 
CXCR3, from secondary lymphoid tissues to the TME [3,8,41] (Fig. 1). 
From CD4 naïve T cells, Tregs could be also induced and activated 
within the TME via antigen presentation by tolerogenic DCs and 
tumor-derived factors, thereby enhancing the suppressive activity of 
Tregs characterized by upregulated levels of CD25 and FoxP3 [42]. 
Tumor cells could induce the proliferation and differentiation of Tregs 
by converting immature DCs in the TME into TGF-β-producing cells 
[43]. In turn, TGF-β is an essential mediator for Treg differentiation and 
survival [44]. Collectively, the accumulation of FoxP3 Tregs within the 
TME can occur by the recruitment of tTregs or pTregs via chemotaxis, 
support of Treg proliferation, differentiation and survival via 
tumor-derived factors, such as TGF-β and IL-10, or possibly via the 
conversion and differentiation of naïve CD4FoxP3- T cells to 
CD4FoxP3 Tregs [18,45]. 
Tregs within the TME orchestrate a complex cellular/molecular 
suppressive network, which involves regulating the activity and 
Fig. 2. Treg-mediated immunosuppres-
sion mechanisms and potential thera-
peutic targets to alleviate 
immunosuppression. A schematic diagram 
illustrates the mechanisms by which Tregs 
mediate immunosuppression within the TME 
and promote tumorigenesis. For example, 
CCR4 Tregs are recruited to the TME via a 
chemotactic gradient mediated by chemo-
kines, CCL17 and CCL22. Highly immuno-
suppressive FoxP3 Tregs release high levels 
of granzyme B and perforin, which act on 
Teffs to induce apoptosis and cytolysis; 
release high levels of TGF-β, IL-10 and IL-35, 
which suppress Teff function and induce 
Blimp-1-mediated T cell exhaustion and 
expression of ICs (PD-1, TIM-3, LAG-3 and 
TIGIT). Highly immunosuppressive FoxP3
Tregs express high levels of ICs. CTLA-4 
binds to B7 ligands resulting in the expres-
sion of indoleamine 2,3-dioxygenase (IDO), 
tryptophan catabolic enzyme, which subse-
quently suppresses APC function and the 
generation of activation signals for T cells. 
Interactions between ICs (on Treg) and their 
ligands (on APC), PD-1/PD-L1, TIM-3/ 
galectin-9, TIGIT/CD155 and CD122, 
VISTA/VSIG-3 and LAG-3/MHCII, also lead 
to the impairment of APC activation, and 
subsequently inhibit T cell activation. 
FoxP3 Tregs express high levels of ectoen-
zymes CD39 and CD73, which catalyze the 
conversion of extracellular adenosine 
triphosphate (ATP) to extracellular adeno-
sine. Adenosine binds to its receptor, aden-
osine 2A (A2A), on Teffs and results in the 
accumulation of intracellular 30-50-cyclic 
adenosine monophosphate (cAMP), which in 
turn inhibits the function of Teffs and sup-
presses their proliferation. Increased 
expression of CD25 on FoxP3 Tregs in-
crease their consumption of IL-2, and there-
fore deprive Teffs of IL-2 and inhibit Teff 
differentiation and proliferation. Targeting 
Treg-mediated immunosuppression mecha-
nisms, for example blocking CCR4 and Treg 
chemotaxis; blocking TGF-β, IL-10 and IL-35 
signaling; blocking CD39, CD73 and 
adenosine-mediated suppression pathway, 
combined blockade of ICs, and blocking 
CD25, could improve clinical outcomes in 
cancer patients and could be used in com-
bination with approved ICIs.   
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differentiation of tumor-associated cells, such as TAMs, MDSCs and 
cancer-associated fibroblasts (CAFs), thereby contributing to immuno-
suppression and tumorigenesis via indirect means [8]. Furthermore, 
Tregs can directly suppress anti-tumor immunity by impairing the 
function of APCs and NK cells and diminishing the activation and pro-
liferation of cytotoxic CD8 T cells and CD4 T effector cells, leading to 
tumor growth and progression [3]. 
3. Mechanisms of Treg-mediated immunosuppression in cancer 
There are different mechanisms by which Tregs promote tumori-
genesis and immunosuppression (Fig. 2), and may lead to resistance of 
cancer against approved ICIs targeting CTLA-4 and PD-1/PD-L1, as 
discussed briefly below. Strategies targeting Treg-mediated immuno-
suppression mechanisms could improve clinical outcomes in cancer 
patients (Fig. 2), and could be used in combination with cancer immu-
notherapies such as ICIs. 
3.1. Increased consumption of IL-2 
Studies on animals showed that IL-2 deficiency led to the reduction 
of Tregs, in particular FoxP3 Tregs, suggesting the importance of IL-2 
signaling not only for the development of Tregs, but also for their sup-
pressive function (9, 59, 60). IL-2 signalling is important for the survival 
and proliferation of both Tregs [46] and Teffs [47]. IL-2 is produced by 
Teffs upon the activation of T cell receptor (TCR) signaling, however, it 
cannot be produced by Tregs [48–50]. Therefore, Tregs and Teffs pre-
sent within the same TME compete for IL-2 consumption [51]. Tregs 
constitutively express high levels CD25, alternatively known as IL-2 
receptor-α chain (IL-2Rα), which bind with a high affinity to IL-2 pro-
duced by activated Teffs [10,46]. Hence, Tregs end up with a higher 
consumption of IL-2 favoring their own survival and supporting their 
suppressive function, causing Teff deprivation of IL-2 and suppressing 
the function of effector immune cells [9,10,46] (Fig. 2). 
3.2. Increased production of IL-10, IL-35, TGF-β and cytolytic molecules 
Tregs are one of the major cellular sources for IL-10 and IL-35 within 
the TME [11,52,53]. The importance of IL-10 [54–58] and IL-35 [53,59] 
in immunosuppression and tumorigenesis has been shown in several 
preclinical models. Increased expression of IL-10 in a melanoma mouse 
model is associated with tumor progression, impairment of DC matu-
ration, inactivation of CD8 T cell function and reduced expression of 
IFN-γ and granzyme B, while its deficiency reduced tumor growth, 
impaired Treg suppressive function and enhanced cytotoxic CD8 T cell 
function [57]. IL-35 secreted by Tregs can promote T cell exhaustion by 
inducing the expression of PD-1, TIM-3 and LAG-3 on Teffs [60], and 
lead to cell cycle arrest and the inhibition of Teff proliferation [61]. 
Sawant et al. showed that IL-10 produced by Tregs, in cooperation with 
IL-35, limits the anti-tumor immune response in mouse tumor models by 
promoting the exhaustion of tumor-infiltrating CD4 and CD8 T cells 
through the induction of Blimp-1-mediated pathway and the upregula-
tion of ICs, including PD-1, TIM-3, LAG-3 and TIGIT [62] (Fig. 2). IL-10 
and IL-35, in turn, are essential for the induction and suppressive ac-
tivity of Tregs [12,63,64]. Similarly, TGF-β is a crucial mediator for 
FoxP3 induction, Treg differentiation, maintenance and suppressive 
activity [65,66]. Secreting high levels of TGF-β is one of the character-
istics of highly immunosuppressive intratumoral Tregs [44,66,67]. 
There is evidence suggesting that TGF-β can influence the composition 
and function of TILs, favoring Treg accumulation and Treg-mediated 
immunosuppression [68–70]. Additionally, Tregs can deplete Teffs in 
the tumor via the release of granzyme B and perforin and the induction 
of cytolysis [13] (Fig. 2). 
3.3. Adenosine-mediated immunosuppression pathway 
The hypoxic environment within the tumor could be responsible for 
the increase of extracellular adenosine, which in turn enhances immu-
nosuppression and promotes tumorigenesis [71]. FoxP3 Tregs express 
high levels of ectoenzymes, CD39 and CD73, and induce the 
adenosine-mediated immunosuppression pathway [72–74], thereby 
inhibiting Teff function and suppressing Teff proliferation [72,75,76] 
(Fig. 2). Adenosine signaling pathway can affect multiple cell types and 
leads to the inhibition of NK activation, impairment of APC function and 
enhancement of Treg function [71]. 
3.4. Upregulation of inhibitory immune checkpoints 
Tregs in the TME express upregulated levels of inhibitory IC re-
ceptors, such as TIM-3, TIGIT, LAG-3, CTLA-4, PD-1 and V-domain 
containing Ig Suppressor of T cell Activation (VISTA) [77,78]. Upregu-
lated levels of these ICs on Tregs can indirectly inhibit the activation of 
Teffs by negatively influencing the function of APCs (via IC-IC ligand 
interaction, Fig. 2), which is essential for Teff activation, as we previ-
ously reviewed in Ref. [77]. CTLA-4 [79–83], PD-1 [84,85], TIM-3 [86, 
87], LAG-3 [88–91], TIGIT [92,93] and VISTA [94,95] on Tregs induce 
inhibitory signals upon their interaction with their respective ligands, 
leading to the inhibition of APC function, as well as Teff activation and 
proliferation within tumor sites [84] (Fig. 2). The overexpression of 
these ICs on Tregs can also positively regulate Treg stability/differ-
entiation and enhance their suppressive activity [77,88,96]. There is 
evidence suggesting that PD-1 can enhance Treg stability by promoting 
FoxP3 expression [14], TIM-3 and TIGIT can increase the suppressive 
activity of Tregs as measured by IL-10, perforin and granzymes pro-
duction [96,97], and VISTA signaling pathway can act on naïve T cells to 
induce their differentiation into Tregs [98]. Collectively, these data 
implicate that the upregulation of ICs on Tregs can increase and support 
the survival, differentiation and function of Tregs by enhancing the 
expression of suppressive cytokines and cytolytic molecules. As a result, 
a positive feedback loop is generated favoring Treg accumulation within 
the tumor, and promoting the induction of Teff apoptosis or the inhi-
bition of Teff activation. It may also negatively influence Th1 polari-
zation via IL-10 and TGF-β. 
4. Prognostic significance of Tregs in cancer 
One of the major factors which facilitates immune evasion and tumor 
growth is the increased ratios of Tregs:CD8 T cells within the TME 
[25–27]. However, there are some conflicting results in regards to the 
prognostic significance of Tregs in certain cancer types, which do not 
support the notion of targeting Tregs for cancer therapy. Table 1 shows 
some of the key studies on the prognostic impact of FoxP3 Tregs in 
various cancers. Studies reported that increased frequency of FoxP3
Tregs within tumors is associated with improved prognosis in some 
cancer types, such as colorectal cancer [99–101], and head and neck 
cancer [102]. It has been proposed that FoxP3 Treg infiltration is 
beneficial for suppressing the inflammatory response to gut microbes in 
early stages of colorectal cancer [103]. Contradictory results rising from 
the assessment of the prognostic impact of Tregs in tumor tissues of head 
and neck cancer patients (Table 1) could be attributed to the random-
ness of Treg quantification; Treg assessment should be subdivided into 
groups based on their localization in the tumor tissue and the prognostic 
impact of each group should be individually examined [102]. 
Increased numbers of FoxP3HeliosPD-1CTLA-4CD39 Tregs 
and exhaustive phenotype of CD4 and CD8 T cells have been detected 
in tumor tissues of breast and colorectal cancer patients, and proposed to 
create an immunosuppressive environment, which favors immune 
evasion and tumor progression [104,105]. Additionally, CTLA-4, LAG-3 
and TIM-3 were mainly co-expressed by tumor-infiltrating 
FoxP3Helios Tregs, and little was co-expressed by FoxP3  Helios- 
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Tregs [106]. 
Up to date, there are many studies reporting the correlation between 
intratumoral Treg infiltration and disease prognosis in various tumor 
types. However, different methodologies were used in these studies to 
determine the level of Tregs in tumor tissue. Some researchers used 
immunohistochemistry slides, while others used tissue microarray [19]. 
Also in some studies, FoxP3 was used as a sole marker for Tregs, while in 
other studies FoxP3, CD25 and CCR4 were used [27]. Additionally, the 
prognostic significance of Tregs is influenced by tumor site, molecular 
subtype and tumor stage [19]. Therefore, the prognostic significance of 
Tregs in cancer remains controversial for some cancer types. 
Meta-analysis of 74 studies encompassing 17 types of cancer (n 
15,512 patients) showed that high intratumoral FoxP3 Treg infiltration 
is associated with poor overall survival (OS) rates in the majority of solid 
tumors studied [19]. Increased levels of intratumoral FoxP3 Tregs have 
been positively correlated with worsened disease outcomes and short OS 
rates in patients with melanoma, breast, glioblastoma, cervical, renal, 
gastric and hepatocellular cancers [19,27,107,108]. In contrast to this, 
high intratumoral FoxP3 Treg infiltration in colorectal, head and neck 
and esophageal cancers was associated with improved disease prognosis 
and higher OS rates [19]; however, the prognostic impact of Tregs in 
colorectal and head/neck cancers remains controversial. A recent 
meta-analysis showed that increased frequencies of Tregs in the 
circulation and tumor tissues of patients with gynecological cancers 
(GCs) can be used as a biomarker for clinical outcomes [109] (Table 1). 
Levels of Tregs in the circulation and tumor tissues in GC patients with 
advanced stages were found to be higher than those with early stages; 
however, no significant associations were found between Treg levels in 
the circulation or tumor tissues and the survival of GC patients [109]. 
Curiel et al. reported elevated numbers of FoxP3CD25 Tregs in 
human ovarian tumor tissues, compared to normal tissues, and 
demonstrated in vivo that recruitment of CCR4 Tregs into tumor tissue 
via chemokine gradient, leads to Treg accumulation and impairs anti- 
tumor immunity in ovarian cancer model [110]. Furthermore, authors 
showed that accumulation of Tregs within tumor tissue correlated with 
poor survival rates in ovarian cancer patients, and could be an inde-
pendent risk factor for death [110] (Table 1). The prognostic signifi-
cance of FoxP3 Tregs could vary with disease stages. Three studies 
reported that increased FoxP3 Treg infiltration in ovarian tumors of 
patients with advanced stages is associated with long OS rates and 
improved disease prognosis [21,111,112]. On the other hand, other 
studies showed that high FoxP3 Tregs infiltration in patients with 
ovarian cancer, regardless of disease stages, is associated with poor 
disease prognosis and short OS rates [19,110]. For pancreatic cancer, 
low FoxP3/granzyme B ratio in tumor tissues has been associated 
with high recurrence-free survival (RFS) rates in patients with left-side 
resected pancreatic ductal adenocarcinoma (PDAC) [113]. Another 
study by Liu et al. showed that Treg/Teff ratios in the circulation of 
patients with unresectable PDAC could be used as a predictor for OS and 
chemotherapeutic response [114]. Authors also showed that elevated 
levels of Tregs in the circulation of patients with unresectable PDAC 
were associated with poor disease prognosis [114]. Studies on gastric 
cancer showed that increased tumor infiltration with FoxP3 Tregs is 
positively correlated with poor prognosis, and short RFS and OS rates in 
patients, while increased tumor-infiltrating CD8 T cells was associated 
with improved disease prognosis, including RFS and OS rates 
[115–117]. Similarly, increased numbers of FoxP3 Tregs in tumor tis-
sues of patients with renal cell carcinoma (RCC) [118], NSCLC [119, 
120] have been associated with poor disease outcomes and short sur-
vival rates (Table 1). Elevated levels of circulating CD4 Treg subsets 
expressing TGF-β and IL-10 have been associated with clinical outcomes 
in untreated NSCLC patients [17]. Moreover, elevated levels of naïve 
Tregs in the circulation correlated with poor clinical outcomes, while 
levels of effector Tregs in the circulation correlated with improved 
prognosis, proposing that targeting Treg recruitment into the TME could 
be beneficial in enhancing anti-tumor immune responses [17]. 
For breast cancer, Bates et al. reported that FoxP3 Treg infiltration 
in invasive breast tumors was positively correlated with high tumor 
grades and positive lymph node status [121]. Patients with breast tu-
mors (invasive and noninvasive) containing high FoxP3 Treg infiltra-
tion had short OS and RFS rates [121]. Furthermore, authors found that 
FoxP3 Treg infiltration had no impact on the survival rates of breast 
cancer patients based on estrogen receptor (ER) subtype; both patient 
subgroups ER and ER  with high FoxP3 Treg infiltration showed no 
difference in survival rates [121]. Another study by Kim et al. demon-
strated that low numbers of tumor-infiltrating CD8 T cells were 
significantly associated with advanced stages (stage III), lymph node 
metastasis and Ki-67 (cell proliferation marker) expression in breast 
cancer [122]. On the contrary, authors found that high numbers of 
tumor-infiltrating FoxP3 Tregs were significantly correlated with 
lymph node metastasis, ER positivity, and Ki-67 and p53 expression 
[122]. Additionally, disease-free survival (DFS) rates of patients with 
non-triple negative breast cancer were significantly associated with the 
number of FoxP3 Tregs [122]. Triple negative breast cancer, on the 
other hand, was positively correlated with low ratios of 
tumor-infiltrating FoxP3 Tregs/CD4 T cells [122]. Meta-analysis of 14 
studies (n  10,259 patients) showed that FoxP3 Treg infiltration in 
breast tumors increased with high histological grade and correlated with 
the lack of ER expression and the expression of human epidermal growth 
Table 1 
Key studies show the prognostic significance of FoxP3 Tregs in cancer.  
Prognostic measure Tumor type Prognostic indicator/ 
clinical outcomes 
Ref. 
High numbers of intratumoral 
FoxP3 Tregs 
Colorectala Improved prognosis 
associated with high 
OS rates 
[101, 
191, 
192] 
High numbers of intratumoral 
FoxP3 Tregs 
Head and 
necka 
Longer RFS and OS 
rates 
[193] 
High levels of tumor- 
infiltrating CD4 FoxP3
Tregs 
Increased intratumoral 
CD8/FoxP3 Tregs ratio 
Colorectala Positive correlation 
with lymph node 
metastasis 
Short survival rates 
[194] 
High levels of tumor- 
infiltrating CD4 FoxP3
Tregs 
Head and 
necka 
Poor prognosis and 
short survival rates 
[124, 
125] 
High numbers of tumor- 
infiltrating FoxP3
lymphocytes 
Lung Poor overall survival 
rates 
[195] 
Elevated levels of 
CD4CD25FoxP3 Tregs in 
the circulation and tumor 
tissue 
Elevated levels of 
CD4CD25FoxP3 Tregs in 
the circulation 
Renal Poor disease prognosis 
Short survival rates 
[196] 
[197] 
High levels of tumor- 
infiltrating CD4 FoxP3
Tregs 
Gastric Positive correlation 
with TNM staging 
Short survival rates 
[117] 
High levels of tumor- 
infiltrating FoxP3
lymphocytes 
Breast Short RFS and OS rates [121, 
198] 
Elevated levels of 
CD4CD25FoxP3 Tregs in 
tumor tissue 
High levels of FoxP3 Tregs 
in tumor tissue 
Ovarian Death hazard and 
inverse correlation 
with survival 
Poor prognosis and 
reduced OS rates 
[110] 
[199] 
High levels of tumor- 
infiltrating 
CD4CD25FoxP3 Tregs 
Pancreatic Positive correlation 
with advanced tumor 
stage, distant 
metastasis and high 
tumor grade 
[200] 
High levels of tumor- 
infiltrating CD4 CD25
FoxP3 Tregs 
Prostate Poor survival rates [201]  
a Refers to contradictory findings/OS  overall survival; RFS  recurrence- 
free-survival. 
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factor 2 (HER2) [123]. In addition, it was reported that FoxP3 Treg 
infiltration in breast tumor tissues was correlated with poor RFS [123] 
(Table 1). Therefore, based on these findings, the prognostic effect of 
FoxP3 Tregs on the clinical outcomes of breast cancer patients can vary 
depending on the histological grade and molecular subtype of tumor. 
5. Therapeutic approaches to target Tregs in combination with 
immune checkpoint inhibitors 
For tumors where FoxP3 Treg infiltration is considered to be a 
prognostic factor, targeting Tregs could be a potential therapeutic 
strategy. These tumors are from a wide range of human cancers, 
including HNSCC [124,125] and localized or metastatic hepatocellular 
[126], breast [121], gastric [127], lung [30], ovarian [110] and cervical 
[128] cancers. Targeting Tregs in cancer patients could increase intra-
tumoral CD8 cytotoxic T cell infiltration, reduce the infiltration of 
myeloid suppressive cells within the TME, enhance the function of APCs 
and suppress tumor growth [8,77]. Although the use of monoclonal 
antibodies (mAbs) against PD-1, PD-L1 and CTLA-4 for treating solid 
tumors has shown a therapeutic efficacy associated with improved 
prognosis and OS rates in patients, tumor recurrence and the emergence 
of tumor resistance against cancer immunotherapy remain a challenge. 
There is an accumulating evidence suggesting that increased number of 
Tregs in tumors is associated with the development of acquired resis-
tance against cancer immunotherapies. 
5.1. Targeting CD25 
Tregs could be targeted via the use of antibodies against CD25 
(Fig. 2). A study using mouse model of head and neck cancer showed 
that radiotherapy with combined blockade of CD25, PD-L1 and TIM-3 
resulted in a prolonged survival response and increased therapeutic ef-
ficacy, compared to radiotherapy with anti-PD-L1/TIM-3 alone [129]. 
Another study by Shimizu et al. showed that targeting CD25 in mouse 
tumor models increased the number of Teffs within the tumor and the 
release of IFN-γ [4]. However, it is worth noting that targeting CD25 
would not be exclusive to Tregs as non-Tregs also express CD25 [130]. 
Various drugs have been developed to test the effect of blocking CD25 in 
hematologic malignancies and going under clinical trials in cancer pa-
tients [131]. Alternatively, it was shown in mouse tumor models that 
intratumoral administration of anti-CD4 mAb in late stages results in the 
depletion of Tregs, downregulation of IL-10, upregulation of IFN-γ, and 
tumor rejection [32], suggesting that the majority of intratumoral CD4
T cells in late tumor stages are Tregs. This implicates that the effect of 
targeting Tregs depends on the timing of treatment application. 
5.2. Targeting FoxP3 expression 
Another Treg marker which could also be targeted is FoxP3. Multiple 
lines of evidence from mouse and human studies demonstrate the 
importance of FoxP3 in Treg function and activity [132–137]. Moreover, 
reduced expression of FoxP3 and IL-10 in induced Tregs upon anti-PD-1 
has been reported, suggesting a potential link between FoxP3 and ac-
tivity of Tregs [138]. Stability of FoxP3 expression is mediated by se-
lective demethylation with the FoxP3 element, Treg-specific 
demethylated region (TSDR) [139]. Using transfection and luciferase 
vector assays, Polansky et al. showed that murine CD4 T cell line car-
rying methylated construct of TSDR lacks the transcriptional activity of 
TSDR, compared to those carrying the insert of demethylated TSDR 
construct [139], suggesting that methylation of TSDR could be used an 
approach for targeting FoxP3 expression. Wang et al. showed that the 
binding of methyl-binding domain 2 (Mdb2) protein to TSDR promotes 
ten-eleven translocation 2 (TET2)-mediated demethylation, which in 
turn induces FoxP3 expression [140], implicating that inhibiting the 
activity of TET2 enzyme could diminish Treg stability. In support of this, 
other studies have shown that using epigenetic modifier (DNA 
methylation agent, for example TET inhibitor) to target TSDR, could be 
beneficial in interrupting the stability of FoxP3 expression in intra-
tumoral Tregs, and therefore diminishing FoxP3 Treg infiltrates in the 
tumor [140–142]. FoxP3 expression can be transiently expressed by 
recently activated Teffs; however, its expression is more prolonged and 
stable in Tregs due to the selective existence of TSDR in natural Tregs, 
which does not occur in other T cell subsets [143]. Hence, reversing 
TSDR demethylation is very specific to Tregs, compared to targeting 
CD25, and may represent a better therapeutic approach for Treg 
depletion. FoxP3 expression in Tregs could be also targeted via other 
epigenetic modulation such as the use of histone deacetylation in-
hibitors and ubiquitylation agents [144]; however, these epigenetic 
modifiers have multiple target genes and their use could as well have 
effects on FoxP3- cells. 
5.3. Targeting PI3K signaling pathway 
Targeting pathways which positively regulate Treg stability, function 
and survival such as phosphatidylinositol 3-kinase (PI3K) signaling 
pathway [145,146] could be more selective in diminishing CD4CD25
Treg proliferation, and has shown a therapeutic efficacy in mouse tumor 
models [145,147,148]. Qin et al. showed that silencing microRNA-126 
(miR-126) in a mouse breast cancer model impairs the activation of 
PI3K pathway, which subsequently reduces the induction and suppres-
sive function of Tregs [149]. Other studies demonstrated that inhibition 
of PI3K signaling in intratumoral Tregs resulted in tumor regression 
associated with reduction in Treg proliferation and increase of CD8 T 
cell activation [145,147,148]. Moreover, the inhibition of PI3K activity 
in combination with anti-PD-1 and/or anti-CTLA-4 mAbs has enhanced 
the therapeutic efficacy and clinical response in murine models of 
melanoma [145] and HNSCC [150]. Together, these findings implicate 
that inhibition of PI3K combined with the blockade of ICs could selec-
tively target Tregs and alleviate Treg-mediated resistance. 
5.4. Targeting chemokine receptors 
Tregs are recruited to the TME in response to a chemotactic gradient 
which is facilitated by chemokine and its receptor; different tumor sites 
are infiltrated with Tregs that express different chemokine receptors 
(CCRs). For instance, CCR6 Tregs are highly infiltrated in tumor tissues 
of patients with breast cancers and hepatocellular carcinoma, while 
tumor tissues of ovarian and gastric cancers are highly infiltrated with 
CCR4 Tregs [151]. Therefore, tumor sites and Treg phenotypes should 
be considered before clinical application of CCR inhibitors. Targeting 
CCR4 which is associated with Treg chemotaxis to tumor sites of 
different cancer types (118–120) could have therapeutic benefits. 
Studies showed that targeting CCR4 via neutralizing antibodies or an-
tagonists could diminish Treg infiltration in tumor sites (118, 121) 
(Fig. 2). Targeting CCR4 could be more selective in diminishing Tregs 
(CD4FoxP3), unlike targeting CD25 which results in the depletion of a 
fraction of non-Tregs (118). It was demonstrated that CCR4 is primarily 
expressed by Tregs in melanoma, and its depletion in PBMCs isolated 
from melanoma patients was able to induce the generation of CD4 and 
CD8 T cells specific for cancer-testis antigens (118). Authors also 
demonstrated that CCR4 blockade in vivo, using anti-CCR4 mAb 
(mogamulizmab), led to the reduction of melanoma-infiltrating Tregs 
(118). Moreover, the blockade of CCR4 in patients with acute T-cell 
leukemia/lymphoma (ATL), a condition characterized by high numbers 
CCR4-expressing Tregs, enhanced the anti-tumor immune response 
mediated by CD4 and CD8 T cells (118), and resulted in the approval 
of using mogamulizmab to treat ATL in Japan (118). The therapeutic 
efficacy of mogamulizmab, as a monotherapy, is under investigation in 
ongoing early phase clinical trials (NCT01929486) (122), or in combi-
nation with either anti-PD-1 mAb (NCT02476123 and NCT02705105), 
anti-PD-L1 mAb (NCT02444793) or anti-CTLA-4 mAb (NCT02301130) 
in advanced solid tumors. 
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5.5. Targeting immunosuppressive cytokines 
The inhibition of Treg function represents another mean of therapy 
by targeting immunosuppressive cytokines including TGF-β, IL-10 and 
IL-35 (Fig. 2). TGF-β signaling could be targeted in cancer to reduce the 
differentiation/suppressive function of Tregs and their survival within 
the TME [152,153]. In vitro, Becker et al. showed microRNA 
(miR-466a-3b) can inhibit the expression of TGF-β2, which subsequently 
diminished the differentiation of FoxP3 Tregs [154]. Other in vitro 
studies by Hou et al. demonstrated the efficacy of TGF-β chimeric anti-
gen receptor (CAR) T cells in alleviating TGF-β-mediated immunosup-
pression, thereby promoting the anti-tumor immune response mediated 
by CD8 and CD4 T cells specific for tumor antigens [155]. Addition-
ally, authors showed that TGF-β chimeric antigen receptor (CAR) T cells 
were able to diminish the induction and differentiation of FoxP3 Tregs 
[155]. These findings proposed targeting TGF-β as a mean of adoptive T 
cell therapy and its potential therapeutic efficacy in cancer. 
A study by Ravi et al. showed that in vitro stimulation of human 
PBMC with IL-2, TGF-β and anti-CD3/anti-CD28-coated beads treated 
with engineered antibodies targeting CTLA4 and TGFβRII simulta-
neously abolished the TGF-β-mediated FoxP3 expression, while the 
single blockade of CTLA-4 in stimulated human PBMC did not show such 
effect [156]. In vivo, authors demonstrated that the simultaneous inhi-
bition of CTLA-4 or PD-L1 with TGF-β signaling, using engineered an-
tibodies, is more effective in reducing tumor-infiltrating Tregs, 
increasing the number of IFN-γCD8 T cells and promoting anti-tumor 
cytotoxic effects in a mouse melanoma model, compared to the single 
inhibition of CTLA-4 or PD-1 [156]. These data implicate that simulta-
neous blockade of ICs and TGF-β signaling may maximize the thera-
peutic efficacy and synergistically improve the clinical and immune 
response compared to the blockade of ICs alone. Based on these findings, 
the dual inhibition of TGF-β and ICs is currently under clinical investi-
gation in various cancer patients [as reviewed in Ref. [153]]. 
The inhibition of IL-10 could be considered as a potential therapeutic 
strategy to target Treg suppressive functions within the TME. Increased 
serum levels of IL-10 have been associated with poor disease prognosis 
and low DFS rates in many patients with solid tumors or hematologic 
malignancies [157], including hepatocellular carcinoma, diffuse large B 
cell lymphoma, melanoma and Hodgkin’s lymphoma [158–161]. 
Elevated levels of IL-10 within the TME have also been associated with 
poor disease prognosis and clinical outcomes in cancer patients [162]. 
IL-10 produced by Tregs could be associated with cancer progression, 
impaired tumor-resident APC activation and suppression of Teff func-
tions and Th17 cells [163]. Sawant et al. showed that IL-10 produced by 
Tregs, in cooperation with IL-35, limits the anti-tumor immune response 
in mouse tumor models by promoting tumor-infiltrating CD4 and CD8
T cell exhaustion through the induction of Blimp-1-mediated T cell 
exhaustion pathway and the upregulation of ICs, including PD-1, TIM-3, 
LAG-3 and TIGIT [62]. Furthermore, it was demonstrated that IL-10 
deficiency in mouse tumor models was able to reduce Treg-mediated 
immunosuppression by reducing the expression of neuropillin on 
Tregs within the TME [57]. This in turn resulted in the simultaneous 
activation of Th1 and Th17 immune response, leading to tumor 
regression and enhanced anti-tumor immunity [57]. Together, these 
data implicate the potential therapeutic benefits of blocking IL-10 pro-
duced by Tregs in cancer. Naing et al. reported that 
PEGlyated-recombinant human IL-10 (PEG-rhuIL-10) increased serum 
levels of IFN-γ, IL-18 and reduced levels of TGF-β in cancer patients with 
advanced solid tumors (Phase I clinical trial, NCT02009449) [164]. In 
addition, treated patients showed some partial clinical responses [164]. 
A phase III clinical trial investigating PEG-rhuIL-10 in combination with 
FOLFOX in metastatic pancreatic cancer patients is currently ongoing 
(NCT02923921). 
The blockade of IL-35 in multiple cancer models has shown to be 
effective in increasing the number of tumor-infiltrating CD4 and CD8
Teffs and reducing tumor growth, thereby proposing that targeting IL-35 
could be beneficial for enhancing the anti-tumor immune response [60]. 
5.6. Targeting CD39, CD73 and adenosine-mediated signaling pathway 
Targeting components of the adenosine signaling pathway in cancer 
could have clinical implications and therapeutic benefits by reducing the 
induction and suppressive function of FoxP3 Tregs. FoxP3 Tregs can 
be induced in vitro upon the stimulation of adenosine receptor (A2AR) 
[165,166], suggesting the potential role of adenosine in Treg induction. 
Tregs lacking expression of CD39 and A2AR have shown limited sup-
pressive activity [76,167,168]. Moreover, inhibitors against CD39 and 
CD73 can reduce the suppressive activity of Tregs [71,169]. 
CD73-deficient mice and the in vivo blockade of CD73 in mouse mela-
noma and colorectal cancer models reduced pulmonary metastasis and 
tumor growth [170]. Results from in vivo models showed the thera-
peutic efficacy of inhibiting A2AR via pharmacological inhibitors, siR-
NAs or antibodies, enhancing anti-tumor immunity, tumor regression 
and improving clinical outcomes [171,172]. 
Targeting CD39, CD73 and adenosine-mediated immunosuppression 
pathway could be beneficial in augmenting the anti-tumor immune 
response against tumor cells, and enhancing the sensitivity to ICIs in the 
case of acquired resistance [72,75,173–175] (Fig. 2). Using syngeneic 
and humanized tumor models, inhibition of CD39 was able to activate 
NLRP3-mediated inflammasome pathway, increase the number of 
intratumoral Teffs, enhance anti-tumor immune response and alleviate 
tumor resistance against anti-PD-1 [176]. The combined blockade of ICs 
and CD73 is under clinical investigation (NCT02503774) [174]. 
Furthermore, targeting adenosine/A2AR signaling combined with CAR 
T cell therapy or ICIs has showed therapeutic efficacy in preclinical 
models [177–179]. Clinical trials to investigate the effect of inhibiting 
A2AR alone or in combination with anti-PD-1/PD-L1 in cancer patients 
are ongoing [178]. 
5.7. Targeting immune checkpoints 
The single or combined blockade of CTLA-4 and PD-1/PD-L1 
pathway(s) in tumors with high numbers of immunosuppressive Tregs 
expressing elevated levels of PD-1 and CTLA-4 can have a therapeutic 
efficacy associated with improved clinical outcomes [180]. However, 
overtime some tumors become less immunogenic resulting in the pro-
duction of more self-antigens to activate Tregs and enhance their sup-
pressive function, and the emergence of compensatory mechanisms to 
escape anti-tumor immunity in response to anti-PD-1/PD-L1 and/or 
anti-CTLA-4 mAb(s) [8,77,181]. Elevated expression of newly emerged 
ICs, such as LAG-3, VISTA, TIM-3 and TIGIT, on intratumoral T cells 
including Tregs act as compensatory pathways to allow immune evasion 
and promote tumor growth/progression in response to anti-PD-1, PD-L1 
or anti-CTLA-4 therapies [77,129,182]. Therefore, it was rationalized 
that combined blockade of LAG-3, VISTA, TIGIT or TIM-3 TIGIT with 
anti-PD-1/PD-L1 mAbs or anti-CTLA-4 mAb could provide alternative 
therapeutic modalities to target Treg-mediated immunosuppression, 
overcome resistance, and maximize clinical outcomes including survival 
rates and disease prognosis (Fig. 2). The therapeutic efficacy of blocking 
TIM-3, TIGIT and LAG-3 in a wide-range of cancer patients is under 
investigation in ongoing clinical trials (as reviewed in Ref. [14,183]). 
Despite this, several studies have shown that ICIs can partially deplete 
Tregs [129,184] or expand them [185–187]. Therefore, other thera-
peutic means, apart from ICIs, are required to target Treg infiltration 
within the TME. 
6. Conclusions and future perspectives 
Although the prognostic significance of Tregs in some cancer types 
remains controversial, the majority of studies have reported positive 
correlations between intratumoral FoxP3 Treg infiltration and poor 
prognosis/clinical outcomes in various tumor types. The 
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controversiality could be attributed to the different methodologies used 
to determine the level of Tregs in tumor tissue [19,27]. Additionally, the 
prognostic significance of Tregs is influenced by tumor site, histological 
features, molecular subtype and tumor stage [19]. Targeting Tregs could 
be beneficial for treating certain cancer types with certain tumor 
stages/molecular type. 
Based on the findings discussed in Section 4, it is imperative to 
consider tumor type, disease stage, histological grade and molecular 
subtype during the assignment of therapeutic protocols to cancer pa-
tients as the prognostic effect of FoxP3 Tregs varied with these pa-
rameters, and their targeting could be beneficial, deleterious or 
negligible. Therefore, understanding the prognostic significance of 
FoxP3 Tregs in various cancers and their contribution to therapy 
resistance could help in the development of more effective targeted 
therapeutic strategies to enhance the clinical outcomes in cancer 
patients. 
Targeting Tregs in combination with ICIs could overcome Treg- 
mediated resistance and increase the sensitivity of tumor cells to ther-
apy, thereby enhancing tumor regression. Targeting the underlying 
mechanisms by which Tregs trigger tumor resistance in response to 
immunotherapies could result in better outcomes associated with 
improved prognosis and survival rates in cancer patients. Several clin-
ical trials are underway to investigate the effect of small molecule in-
hibitors, epigenetic modifiers, mAbs targeting CD25 and chemokine 
receptors, and the combined blockade of multiple ICs [174,183, 
188–190]. 
Different markers have been used to quantify the levels of FoxP3-
Tregs; some studies have used FoxP3 as the sole marker, while other 
studies have used CD25 and/or CCR4 in addition to FoxP3 [19]. 
Therefore, consistency in markers selection and careful analyses are 
required to determine the levels of Tregs in tumor tissues, and to char-
acterize their phenotypes and determine their prognostic significance 
across different tumor types/stages/histological and molecular sub-
types. This should help in designing more improved immunotherapeutic 
protocols and determining whether Treg targeting is a suitable treat-
ment for patients with certain solid tumors based on the clinical and 
histopathological parameters. Additionally, it is important to monitor 
the number and characterize the phenotype of Tregs before and after the 
application of ICIs to identify novel predictive biomarkers which could 
be associated with Treg-mediated resistance in response to ICIs. 
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